Renaissance Technologies LLC reduced its stake in Catalent (NYSE:CTLT) by 37.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,161,400 shares of the company’s stock after selling 686,900 shares during the period. Renaissance Technologies LLC owned approximately 0.87% of Catalent worth $47,710,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently modified their holdings of the company. Champlain Investment Partners LLC increased its holdings in shares of Catalent by 10.9% during the fourth quarter. Champlain Investment Partners LLC now owns 3,043,715 shares of the company’s stock worth $125,036,000 after buying an additional 298,015 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Catalent by 755.3% during the fourth quarter. American Century Companies Inc. now owns 2,631,643 shares of the company’s stock worth $108,108,000 after buying an additional 2,323,971 shares in the last quarter. Earnest Partners LLC increased its holdings in shares of Catalent by 0.5% during the third quarter. Earnest Partners LLC now owns 2,570,156 shares of the company’s stock worth $102,601,000 after buying an additional 12,652 shares in the last quarter. Macquarie Group Ltd. increased its holdings in shares of Catalent by 15.8% during the third quarter. Macquarie Group Ltd. now owns 2,069,323 shares of the company’s stock worth $82,607,000 after buying an additional 282,559 shares in the last quarter. Finally, Brown Advisory Inc. increased its holdings in shares of Catalent by 4.3% during the fourth quarter. Brown Advisory Inc. now owns 2,031,955 shares of the company’s stock worth $83,473,000 after buying an additional 83,441 shares in the last quarter. Institutional investors and hedge funds own 99.89% of the company’s stock.
NYSE CTLT traded down $0.74 during trading hours on Friday, hitting $39.00. The company’s stock had a trading volume of 677,182 shares, compared to its average volume of 766,169. The company has a debt-to-equity ratio of 2.66, a quick ratio of 1.78 and a current ratio of 2.22. The stock has a market cap of $5,298.09, a price-to-earnings ratio of 28.89, a PEG ratio of 2.30 and a beta of 1.53. Catalent has a 52 week low of $27.48 and a 52 week high of $47.87.
Catalent (NYSE:CTLT) last posted its quarterly earnings data on Monday, February 5th. The company reported $0.41 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.10. The firm had revenue of $606.30 million during the quarter, compared to analyst estimates of $565.05 million. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The company’s revenue for the quarter was up 25.3% on a year-over-year basis. During the same quarter last year, the business posted $0.27 EPS. sell-side analysts predict that Catalent will post 1.52 EPS for the current year.
In other Catalent news, SVP William Downie sold 9,082 shares of the stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $41.80, for a total value of $379,627.60. Following the completion of the sale, the senior vice president now owns 46,986 shares in the company, valued at approximately $1,964,014.80. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 1.70% of the company’s stock.
CTLT has been the subject of a number of recent research reports. Royal Bank of Canada initiated coverage on Catalent in a report on Wednesday, December 13th. They issued an “outperform” rating and a $46.00 price objective for the company. Zacks Investment Research downgraded Catalent from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. First Analysis initiated coverage on shares of Catalent in a research report on Friday, January 5th. They set an “equal weight” rating on the stock. Goldman Sachs initiated coverage on shares of Catalent in a research report on Wednesday, January 24th. They set a “buy” rating and a $50.00 price target on the stock. Finally, Stephens cut shares of Catalent from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, February 6th. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $45.75.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/07/catalent-inc-ctlt-stake-lowered-by-renaissance-technologies-llc.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.